Kato Yasuhiro, Morita Takayoshi, Kumanogoh Atsushi
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Department of Immunopathology, Immunology Frontier Research Center (iFReC), Osaka University, Suita, Osaka, Japan.
Inflamm Regen. 2023 Jan 6;43(1):1. doi: 10.1186/s41232-022-00247-1.
Coronavirus disease 2019 (COVID-19), which spread worldwide from Wuhan, China, in 2019, appeared for a time to be overcome by the remarkable efficacy of mRNA vaccines; however, new variants of severe acute respiratory syndrome coronavirus 2 have emerged and remain rampant. The involvement of the virus in the emergence of variant strains and the relationship between vaccine efficacy and immunosuppressive drugs have attracted significant attention, particularly with regard to patients with autoimmune inflammatory rheumatic disease (AIRD) who take immunosuppressive drugs. This review outlines the relationship between mRNA vaccines, one of the key strategies against COVID-19, and AIRD and discusses the immune response elicited by mRNA vaccines. Furthermore, the impact of immunosuppressive agents on the mRNA vaccine-induced immune response in patients with AIRD and side effects of the vaccine, such as exacerbation of the underlying disease, is outlined.
2019年冠状病毒病（COVID-19）于2019年从中国武汉蔓延至全球，一度似乎被mRNA疫苗的显著疗效所战胜；然而，严重急性呼吸综合征冠状病毒2的新变种不断出现且仍在肆虐。病毒在变种毒株出现过程中的作用以及疫苗效力与免疫抑制药物之间的关系备受关注，尤其是对于服用免疫抑制药物的自身免疫性炎性风湿病（AIRD）患者。本综述概述了作为抗击COVID-19关键策略之一的mRNA疫苗与AIRD之间的关系，并讨论了mRNA疫苗引发的免疫反应。此外，还概述了免疫抑制剂对AIRD患者mRNA疫苗诱导的免疫反应的影响以及疫苗的副作用，如基础疾病的加重。
